29 research outputs found
Cardiovascular risk and obesity
La obesidad es una enfermedad crónica de carácter multifactorial que ha alcanzado proporciones epidémicas a nivel global, representando una compleja condición médica con serias consecuencias sociales y psicológicas. El exceso de la adiposidad visceral se encuentra asociado con una plétora de disfunciones metabólicas (resistencia a la insulina, dislipidemia aterogénica, hipertensión arterial, disminución de la fibrinólisis, aumento del riesgo de trombosis, inflamación endotelial) que incrementan el riesgo de enfermedad cardiovascular. Las estrategias planteadas para su correcto abordaje terapéutico deben estar acorde con la gravedad del sobrepeso, la presencia de enfermedades crónicas coexistentes y las limitaciones funcionales de cada individuo.Obesity is a chronic multifactorial disease that has reached global epidemic proportions, representing a complex medical condition with serious social and psychological consequences. The excess of visceral adiposity is associated with a plethora of metabolic dysfunctions (insulin resistance, atherogenic dyslipidemia, hypertension, decreased fibrinolysis, increased risk of thrombosis, endothelial inflammation) that increase the risk of cardiovascular disease. The strategies proposed for the correct therapeutic approach must be in accordance with the severity of overweight, the presence of chronic coexisting diseases and the functional limitations of each individual
Dose volume histogram constraints in patients with soft tissue sarcomas of the extremities and the superficial trunk treated with surgery and perioperative HDR brachytherapy
Background: Wound healing complications (WHC), osteoradionecrosis (ORN), and nerve damage (ND) are
common adverse effects in adult patients with soft tissue sarcomas of the extremities and the superficial
trunk treated with surgery and perioperative high dose rate brachytherapy (PHDRB) alone or combined
with external beam radiotherapy (EBRT).
Rationale: Analysis of the treatment factors contributing to these complications can potentially minimize
their occurrence and severity.
Patients: A total of 169 patients enrolled in two parallel prospective studies were included in this analysis. Previously Unirradiated cases (Group 1; n = 139) were treated with surgical resection, 16–24 Gy of
PHDRB and 45 Gy of EBRT. Adjuvant chemotherapy was given to selected patients with high-grade
tumors. Previously irradiated cases (Group 2; n = 30) were treated with surgical resection and 32–
40 Gy of PHDRB without further EBRT.
Methods: Patient factors, tumor factors, surgical factors, PHDRB factors and EBRT factors were analyzed
using Cox univariate and multivariate analysis.
Results: In Previously Unirradiated cases, WHC, ORN and ND occurred in 38.8%, 5.0% and 19.4%.
Multivariate analysis indicated that WHC increased with CTV size (p = 0.02) and CTV2cm3 Physical dose
(p = 0.02). ORN increased with Bone2cm3 EQD2 67 Gy (p = 0.01) and ND was more frequent in patients
with TV100 DVH-based dose (tissue volume encompassed by the 100% isodose) 84 Gy (p < 0.01). In
Previously Irradiated cases, WHC, ORN and ND occurred in 63.3%, 3.3% and 23.3%. Multivariate analysis
showed that WHC was more frequent in patients with Skin2cm3 Lifetime EQD2 84 Gy (p = 0.01) and
ND was more frequent after CTVD90 Physical Doses 40 Gy (p < 0.01).
Conclusions: WHC in Previously Unirradiated patients can be minimized by using a more conservative
CTV definition together with a meticulous implant technique and planning aimed to minimize hyperdose
CTV2cm3 areas. In Previously Irradiated patients WHC may be mimimized considering Lifetime EQD2
Skin2cm3 doses. ORN can be reduced by using the Bone2cm3 EQD2 constraint. ND occurs more frequently
in patients with large tumors receiving high treated volume doses, but no specific constraints can be recommended due to the lack of peripheral nerve definition during brachytherapy planning
Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study
Summary
Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally.
Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies
have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of
the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income
countries globally, and identified factors associated with mortality.
Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to
hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis,
exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a
minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical
status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary
intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause,
in-hospital mortality for all conditions combined and each condition individually, stratified by country income status.
We did a complete case analysis.
Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital
diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal
malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome
countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male.
Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3).
Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income
countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups).
Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome
countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries;
p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients
combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11],
p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20
[1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention
(ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety
checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed
(ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of
parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65
[0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality.
Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome,
middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will
be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger
than 5 years by 2030
Obesidad y riesgo de enfermedad cardiovascular
Obesity is a chronic multifactorial disease that has reached global epidemic proportions, representing a complex medical condition with serious social and psychological consequences. The excess of visceral adiposity is associated with a plethora of metabolic dysfunctions (insulin resistance, atherogenic dyslipidemia, hypertension, decreased fibrinolysis, increased risk of thrombosis, endothelial inflammation) that increase the risk of cardiovascular disease. The strategies proposed for the correct therapeutic approach must be in accordance with the severity of overweight, the presence of chronic coexisting diseases and the functional limitations of each individual.La obesidad es una enfermedad crónica de carácter multifactorial que ha alcanzado proporciones epidémicas a nivel global, representando una compleja condición médica con serias consecuencias sociales y psicológicas. El exceso de la adiposidad visceral se encuentra asociado con una plétora de disfunciones metabólicas (resistencia a la insulina, dislipidemia aterogénica, hipertensión arterial, disminución de la fibrinólisis, aumento del riesgo de trombosis, inflamación endotelial) que incrementan el riesgo de enfermedad cardiovascular. Las estrategias planteadas para su correcto abordaje terapéutico deben estar acorde con la gravedad del sobrepeso, la presencia de enfermedades crónicas coexistentes y las limitaciones funcionales de cada individuo
Hipertensión en el embarazo
Hypertensive disorders during pregnancy are frequent complications considered an important cause of maternal and/or fetal morbidity and mortality. The various current guidelines on the management of hypertension during pregnancy agree to treat patients with blood pressure ≥ 160/105-110 mmHg due to a high risk of stroke, and to normalize the blood pressure to < 140/90 if there is end-organ damage. The evidence concludes that treatment of low to moderate hypertension reduces the risk to develop uncontrolled hypertension, but does not prevent preeclampsia. Regarding the choice of drug, none of the recommended agents is considered a first option because no data support either of them.Los trastornos hipertensivos durante el embarazo son complicaciones muy frecuentes consideradas causa importante de morbilidad y mortalidad materna y/o fetal. Sobre el manejo de la hipertensión durante la gestación, las diversas guías actuales coinciden en tratar la presión arterial si es ≥ 160/105-110 mmHg por el elevado riesgo de accidente cerebrovascular (stroke) asociado, y en normalizar la presión a < 140/90 si hay compromiso de órgano blanco. Sobre el tratamiento de la hipertensión leve-moderada, la evidencia concluye que reduce el riesgo de desarrollar hipertensión no controlada, pero no previene la preeclampsia. En lo que se refiere a la elección de un fármaco, entre los agentes recomendados, ningún agente específico es la primera opción porque no hay datos que apoyen uno sobre otro
Dose volume histogram constraints in patients with soft tissue sarcomas of the extremities and the superficial trunk treated with surgery and perioperative HDR brachytherapy
Background: Wound healing complications (WHC), osteoradionecrosis (ORN), and nerve damage (ND) are
common adverse effects in adult patients with soft tissue sarcomas of the extremities and the superficial
trunk treated with surgery and perioperative high dose rate brachytherapy (PHDRB) alone or combined
with external beam radiotherapy (EBRT).
Rationale: Analysis of the treatment factors contributing to these complications can potentially minimize
their occurrence and severity.
Patients: A total of 169 patients enrolled in two parallel prospective studies were included in this analysis. Previously Unirradiated cases (Group 1; n = 139) were treated with surgical resection, 16–24 Gy of
PHDRB and 45 Gy of EBRT. Adjuvant chemotherapy was given to selected patients with high-grade
tumors. Previously irradiated cases (Group 2; n = 30) were treated with surgical resection and 32–
40 Gy of PHDRB without further EBRT.
Methods: Patient factors, tumor factors, surgical factors, PHDRB factors and EBRT factors were analyzed
using Cox univariate and multivariate analysis.
Results: In Previously Unirradiated cases, WHC, ORN and ND occurred in 38.8%, 5.0% and 19.4%.
Multivariate analysis indicated that WHC increased with CTV size (p = 0.02) and CTV2cm3 Physical dose
(p = 0.02). ORN increased with Bone2cm3 EQD2 67 Gy (p = 0.01) and ND was more frequent in patients
with TV100 DVH-based dose (tissue volume encompassed by the 100% isodose) 84 Gy (p < 0.01). In
Previously Irradiated cases, WHC, ORN and ND occurred in 63.3%, 3.3% and 23.3%. Multivariate analysis
showed that WHC was more frequent in patients with Skin2cm3 Lifetime EQD2 84 Gy (p = 0.01) and
ND was more frequent after CTVD90 Physical Doses 40 Gy (p < 0.01).
Conclusions: WHC in Previously Unirradiated patients can be minimized by using a more conservative
CTV definition together with a meticulous implant technique and planning aimed to minimize hyperdose
CTV2cm3 areas. In Previously Irradiated patients WHC may be mimimized considering Lifetime EQD2
Skin2cm3 doses. ORN can be reduced by using the Bone2cm3 EQD2 constraint. ND occurs more frequently
in patients with large tumors receiving high treated volume doses, but no specific constraints can be recommended due to the lack of peripheral nerve definition during brachytherapy planning